Additionally, their activation of key receptors, such as GPR41, GPR43, and GPR109A, underscores the therapeutic potential of targeting SCFA production and the gut microbiota in CKD management (Figure 3). This evidence concerns the gene FFAR3 and chronic kidney disease.